Profile image
By [email protected]
Contributor profile | More stories
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

Antibacterial drugs market will hit $35.6 billion by 2022, as efforts increase to tackle antimicrobial resistance, says New Research at Market Reports Center

Tuesday, February 14, 2017 0:09
% of readers think this story is Fact. Add your two cents.

(Before It's News)

The antibacterial drugs market is set to grow from $27.7 billion in 2015 to $35.6 billion by 2022, representing a compound annual growth rate of 3.97%, according to business intelligence at Market Reports Center.

Latest report states that emerging companies and the approvals of new products will drive this growth, along with the continued success of the established marketed products Infanrix, which vaccinates against diphtheria, tetanus and pertussis, and Augmentin, which is amoxicillin sodium and clavulanate potassium.

Read more about report at https://marketreportscenter.com/reports/508240/global-antibacterial-drugs-market-to-2022-vaccines-retain-market-prominence-while-pipeline-offers-innovative-approaches-to-tackling-antimicrobial-resistance

The antibacterial drug market covers the drugs used in the prophylaxis and treatment of bacterial infections. With a growing global concern over antimicrobial resistance and its progressive growth, there is a pronounced need for innovation within this market. This report considers the key developments in this market, with particular focus on drugs indicated for use in pneumonia, methicillin-resistant staphylococcus aureus (MRSA), sepsis and tuberculosis.

Drugs for the prevention of bacterial infections are typically vaccines, which help to train the body’s immune system to fight off specific infections, and can therefore help to prevent infections of certain bacterial strains. However, several prophylactic monoclonal antibodies are also currently in development.

Drugs for the treatment of bacterial infections are slightly more varied. Most common are beta-lactam antibiotics, which include the very widely prescribed penicillin. However, bacteria have developed resistance to penicillin by producing beta-lactamase enzymes that break open the beta-lactam ring found in these antibiotics, rendering them ineffective. As a result modern beta-lactams are frequently combination drugs of a beta-lactam and a beta-lactamase inhibitor.

Reqest sample from report at https://marketreportscenter.com/request-sample/508240

In addition to beta-lactams there are several other classes of drugs used to treat bacterial infections. These include fluoroquinolones, which inhibit DNA gyrase and/or topoisomerase IV; and protein synthesis inhibitors, which have applications within the treatment of bacteria that are resistant to beta-lactam antibiotics. However, bacterial resistance has also developed against these drugs, and as such there is a gap in the market for a new generation of drugs that are effective against drug-resistant bacteria.

The antibacterial market is currently dominated by vaccines, in particular those for the prevention of pneumococcal infections, diphtheria, tetanus and pertussis. However, recent years have seen key additions in the form of therapies for antibiotic-resistant bacteria, including strains with multi-drug resistance. The number of such products is expected to increase drastically between 2016 and 2022.

Check Discount on report at https://marketreportscenter.com/request-discount/508240

Thomas Jarratt, Associate Analyst for Research, explains: “In an attempt to tackle antimicrobial resistance, many companies are investing in the development of products active against bacteria that are known to be resistant to established classes of antibacterials. The use of protein synthesis inhibitors, for example, is expected to increase dramatically over the forecast period as a result of their effectiveness in treating drug-resistant bacterial infections.”

With many protein synthesis inhibitors now off-patent, and with bacteria having developed resistance to a wide range of these drugs, Research believes several of the pipeline drugs for the next-generation of protein synthesis will be approved and enter the market within the forecast period, and will benefit from the commercial focus on treating drug-resistant infections. These include Solithera (solithromycin), Arikace (amikacin sulfate), Cadazolid (cadazolid), and Plazomicin (plazomicin sulfate).

Jarratt continues: “Despite this influx of new protein synthesis inhibitors and the release of several new cell-wall synthesis inhibitors, vaccines will still be the leading revenue generating drugs in the antibacterial drugs market. Indeed, the lack of biosimilars for antibacterial vaccines means that generic competition does not impact on sales as it does for other types of drugs, and many developed countries implement schedules for vaccines preventing certain indications.

“Merck’s blockbuster Prevnar, for example, has benefited greatly from this, and its efficacy in infants for the prevention of 13 serotypes of streptococcus pneumonia, the causative agent in pneumonia, has led to widespread global usage in vaccination schedules, culminating in very high revenue.”

Scope of report

Antibiotic resistance has caused a surge in the development of antibiotics:

- How big is the antibiotic pipeline?

- How are companies attempting to overcome antibiotic resistance? The antibacterial drug market is forecast to rise from around $27.1 billion in 2015 to $35.6 billion in 2022:

- How much will the approval of new products and the patent expiries of existing ones contribute to this market growth?

- Will vaccines continue to drive market revenue? The pipeline contains a range of molecular targets:

- Which molecular targets are most popular in the current pipeline?

- How many late-stage products are active against drug-resistant bacteria?

- What are the commercial prospects for the most promising late-stage pipeline products? Big Pharma maintains a strong presence within the antibacterial drug market:

- Which of the leading companies are expected to have the highest share of the market by 2022?

- Which of the leading pharmaceutical companies are expected to bring new products to market during the forecast period?

- Which companies rely heavily of revenues derived from antibacterial drugs?

About Market Reports Center;

Market Reports Center is an e-commerce platform obliging the needs of knowledge workers, experts, professionals who are subject to market research information for their work, or to make strategic business decisions. We are dedicated to create a comprehensive offering of market research which is accurate, credible and affordable.

Market Reports Center currently has more than 4,00,000 plus titles and 50+ Publishers on our platform and growing consistently. We cover more than 35 industry verticals being: Automotive, Electronics, Manufacturing, Pharmaceuticals, Healthcare, Chemicals, Construction, Agriculture, Food, Beverages, Banking & Finance, Media and Government, Public Sector Studies.

Connect for more details:

Sam Collins

Market Reports Center

1-646-883-3044 (US)

Email: [email protected]

Website: https://marketreportscenter.com

Follow us on LinkedIn: https://www.linkedin.com/company/market-reports-center

Read our blog: https://marketreportscenter.com/blog/

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories
 

Featured

 

Top Global

 

Top Alternative

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.